Yang, Lan, and Aixia Ma. 2023. “Cost-Utilities Analysis of Polatuzumab Vedotin Combined With Bendamustine and Rituximab for Relapsed Refractory Diffuse Large B-Cell Lymphoma Which Is Unsuited for Hematopoietic Stem Cell Transplantation”. Frontiers in Business, Economics and Management 8 (3): 178-84. https://doi.org/10.54097/fbem.v8i3.7835.